# ARID4B

## Overview
ARID4B is a gene that encodes the AT-rich interaction domain 4B protein, which is a member of the ARID family of proteins. This protein is primarily involved in chromatin remodeling and transcriptional regulation, functioning as a component of the mSIN3A histone deacetylase complex. The ARID4B protein contains several conserved domains, including an ARID domain, a chromobarrel domain, and hybrid Tudor domains, which facilitate its interactions with DNA and histones. These interactions are crucial for its role in epigenetic regulation and gene expression modulation. ARID4B is expressed in various tissues, with notable abundance in the testis, and is frequently associated with human carcinomas. Its involvement in cancer biology is complex, as it can act as both a tumor promoter and suppressor depending on the cellular context (Wu2015Androgen; WILSKER2005Nomenclature; Terzi2020ARID4B).

## Structure
The ARID4B protein is a member of the ARID family, characterized by the presence of an ARID domain, which is approximately 100 amino acids long and features a helix-turn-helix (HTH) motif responsible for DNA binding (Korn2022Structures). This domain is crucial for the protein's function in chromatin remodeling and transcriptional regulation. ARID4B also contains a chromobarrel domain, which is hypothesized to bind histone methyl marks due to an aromatic cage, although experimental results have been conflicting (Deák2021Missense). 

The protein includes hybrid Tudor domains (HTDs), with HTD-1 involved in DNA binding, supported by a positively charged surface, and HTD-2 lacking an aromatic cage for histone binding (Deák2021Missense). ARID4B is part of the mSin3A corepressor complex, which includes histone deacetylases Hdac1/2, playing a role in both transcriptional repression and activation (Terzi2020ARID4B). 

ARID4B is known to exist in multiple isoforms due to alternative splicing, which may influence its role in cellular processes. The protein's expression is tightly regulated, being abundant primarily in the testis and frequently expressed in human carcinomas (WILSKER2005Nomenclature).

## Function
ARID4B is a protein involved in chromatin remodeling and transcriptional regulation, playing a crucial role in modulating gene expression. It is a component of the mSIN3A histone deacetylase complex, which is involved in chromatin remodeling and gene expression regulation (Winter2012Allelic). ARID4B contains conserved domains, including a Tudor domain, an ARID domain, and a chromodomain, which facilitate DNA-binding and interactions with methylated histones (Wu2006Deficiency). These interactions are essential for maintaining proper epigenetic regulation and imprinting, particularly in controlling maternal-specific trimethylation and DNA methylation at the Prader-Willi Syndrome Imprinting Center (PWS-IC) (Wu2006Deficiency).

In the context of spermatogenesis, ARID4B functions as a coactivator of the androgen receptor (AR) in Sertoli cells, which are essential for the development of male germ cells. It facilitates the transcriptional activation of AR-responsive genes, such as Rhox5 and Cldn3, which are crucial for germ cell survival and the maintenance of the blood-testis barrier, respectively (Wu2015Androgen). The absence of ARID4B in Sertoli cells leads to structural defects in the seminiferous tubules, increased apoptosis, and impaired spermatogenesis (Wu2015Androgen).

## Clinical Significance
The ARID4B gene is implicated in various cancers, including prostate and breast cancer, due to its role in chromatin remodeling and transcriptional regulation. In prostate cancer, ARID4B is often amplified and overexpressed, particularly in PTEN-deficient cases, where it activates the PI3K-AKT signaling pathway, promoting tumor progression and recurrence (Wu2019Identification). Its expression is associated with increased risk of prostate-specific antigen recurrence, indicating its role in cancer development and recurrence (Wu2019Identification).

In breast cancer, ARID4B is identified as a progression modifier gene, with high expression levels linked to poor clinical outcomes, especially in ER-positive tumors. It promotes tumor growth and metastasis by interacting with chromatin-modifying complexes and regulating gene networks (Winter2012Allelic). Mutations in ARID4B, such as frameshift mutations, are associated with reduced survival rates in breast cancer patients, suggesting these mutations may lead to over-activation of cancer pathways (GonzalezSalinas2023Heterozygous).

In contrast, ARID4B acts as a tumor suppressor in certain contexts, such as in leukemias, where its downregulation or mutations can lead to leukemic transformation (GonzalezSalinas2023Heterozygous). These findings highlight the complex role of ARID4B in cancer biology, acting as both a promoter and suppressor depending on the context.

## Interactions
ARID4B is a protein that participates in various physical interactions with other proteins and nucleic acids, playing a significant role in chromatin remodeling and transcriptional regulation. It is a component of the mSIN3A histone deacetylase complex, where it interacts with proteins such as mSIN3A and mSDS3. These interactions are crucial for its role in epigenetic regulation and cancer progression (Winter2012Allelic). ARID4B also interacts with the breast cancer metastasis suppressor BRMS1, which is part of the same protein family and associates with the mSIN3A complex. This interaction has been confirmed through proteomics screens and co-immunoprecipitation experiments (Winter2012Allelic).

ARID4B preferentially interacts with histone deacetylase 1 (HDAC1) over HDAC2, as demonstrated by coimmunoprecipitation and Proximity Ligation Assay (PLA) results (Terzi2020ARID4B). It also forms a complex with ARID4A, another member of the ARID family, and both proteins are involved in chromatin remodeling by binding to methylated lysines on histones H3 and H4 (Wu2008Identification). These interactions highlight ARID4B's role in regulating gene expression and its involvement in cancer-related pathways.


## References


[1. (Wu2008Identification) M.-Y. Wu, K. W. Eldin, and A. L. Beaudet. Identification of chromatin remodeling genes arid4a and arid4b as leukemia suppressor genes. JNCI Journal of the National Cancer Institute, 100(17):1247–1259, August 2008. URL: http://dx.doi.org/10.1093/jnci/djn253, doi:10.1093/jnci/djn253. This article has 67 citations.](https://doi.org/10.1093/jnci/djn253)

[2. (Wu2015Androgen) Ray-Chang Wu, Yang Zeng, I-Wen Pan, and Mei-Yi Wu. Androgen receptor coactivator arid4b is required for the function of sertoli cells in spermatogenesis. Molecular Endocrinology, 29(9):1334–1346, September 2015. URL: http://dx.doi.org/10.1210/me.2015-1089, doi:10.1210/me.2015-1089. This article has 17 citations.](https://doi.org/10.1210/me.2015-1089)

[3. (Korn2022Structures) Sophie Marianne Korn and Andreas Schlundt. Structures and nucleic acid-binding preferences of the eukaryotic arid domain. Biological Chemistry, 403(8–9):731–747, February 2022. URL: http://dx.doi.org/10.1515/hsz-2021-0404, doi:10.1515/hsz-2021-0404. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.1515/hsz-2021-0404)

[4. (Winter2012Allelic) Scott F. Winter, Luanne Lukes, Renard C. Walker, Danny R. Welch, and Kent W. Hunter. Allelic variation and differential expression of the msin3a histone deacetylase complex gene arid4b promote mammary tumor growth and metastasis. PLoS Genetics, 8(5):e1002735, May 2012. URL: http://dx.doi.org/10.1371/journal.pgen.1002735, doi:10.1371/journal.pgen.1002735. This article has 42 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1371/journal.pgen.1002735)

5. (Deák2021Missense) Missense variants reveal functional insights into the human ARID family of gene regulators. This article has 0 citations.

[6. (WILSKER2005Nomenclature) D WILSKER, L PROBST, H WAIN, L MALTAIS, P TUCKER, and E MORAN. Nomenclature of the arid family of dna-binding proteins. Genomics, 86(2):242–251, August 2005. URL: http://dx.doi.org/10.1016/j.ygeno.2005.03.013, doi:10.1016/j.ygeno.2005.03.013. This article has 129 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.ygeno.2005.03.013)

[7. (GonzalezSalinas2023Heterozygous) Fernando Gonzalez-Salinas, Jessica Herrera-Gamboa, Rocio Rojo, and Victor Trevino. Heterozygous knockout of arid4b using crispr/cas9 attenuates some aggressive phenotypes in a breast cancer cell line. Genes, 14(12):2184, December 2023. URL: http://dx.doi.org/10.3390/genes14122184, doi:10.3390/genes14122184. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/genes14122184)

[8. (Wu2019Identification) Ray-Chang Wu, In-Chi Young, Yu-Fang Chen, Sung-Ting Chuang, Antoun Toubaji, and Mei-Yi Wu. Identification of the pten-arid4b-pi3k pathway reveals the dependency on arid4b by pten-deficient prostate cancer. Nature Communications, September 2019. URL: http://dx.doi.org/10.1038/s41467-019-12184-8, doi:10.1038/s41467-019-12184-8. This article has 34 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-019-12184-8)

[9. (Terzi2020ARID4B) Nihal Terzi Cizmecioglu, Jialiang Huang, Ezgi G. Keskin, Xiaofeng Wang, Idil Esen, Fei Chen, and Stuart H. Orkin. Arid4b is critical for mouse embryonic stem cell differentiation towards mesoderm and endoderm, linking epigenetics to pluripotency exit. Journal of Biological Chemistry, 295(51):17738–17751, December 2020. URL: http://dx.doi.org/10.1074/jbc.ra120.015534, doi:10.1074/jbc.ra120.015534. This article has 17 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.ra120.015534)

[10. (Wu2006Deficiency) Mei-Yi Wu, Ting-Fen Tsai, and Arthur L. Beaudet. Deficiency of rbbp1/arid4a and rbbp1l1/arid4b alters epigenetic modifications and suppresses an imprinting defect in the pws/as domain. Genes &amp; Development, 20(20):2859–2870, October 2006. URL: http://dx.doi.org/10.1101/gad.1452206, doi:10.1101/gad.1452206. This article has 80 citations.](https://doi.org/10.1101/gad.1452206)